VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Growth in Short Interest

Posted by Stanley Muller on Jul 30th, 2026

VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 183,974 shares, an increase of 76.3% from the June 30th total of 104,336 shares. Based on an average trading volume of 2,270,132 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.6% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, VYNE Therapeutics presently has an average rating of “Reduce”.

Get Our Latest Stock Analysis on VYNE Therapeutics

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Anson Funds Management LP bought a new position in shares of VYNE Therapeutics in the 4th quarter valued at about $739,000. Nantahala Capital Management LLC bought a new stake in shares of VYNE Therapeutics during the fourth quarter worth approximately $580,000. T3 Companies LLC bought a new stake in shares of VYNE Therapeutics during the fourth quarter worth approximately $548,000. ADAR1 Capital Management LLC lifted its holdings in VYNE Therapeutics by 319.2% in the first quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock valued at $636,000 after buying an additional 810,108 shares during the period. Finally, KVP Capital Advisors LP acquired a new position in VYNE Therapeutics in the fourth quarter valued at approximately $290,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Stock Performance

Shares of VYNE opened at $28.32 on Thursday. The firm has a market capitalization of $18.98 million, a price-to-earnings ratio of -74.54 and a beta of 2.00. The business’s fifty day moving average price is $33.82 and its two-hundred day moving average price is $31.49. VYNE Therapeutics has a 52 week low of $14.03 and a 52 week high of $79.75.

VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last released its earnings results on Friday, May 15th. The company reported ($4.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.00) by $5.00. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.20 million.

VYNE Therapeutics Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were issued a dividend of $19.00 per share.

VYNE Therapeutics Company Profile

(Get Free Report)

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.